Open Access
Review Article

September-October 2026, Vol. 02 (5), 27-44

International Journal of Pharmaceutical

Research and Medicinal Plants

(An International Peer Reviewed Journal)

Phytochemical Nanocarriers: Translating Traditional Botanical
Therapeutics into Modern Nanomedicine

Abhishek Tripathi*
and Harroshandeep Kaur Phull

University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab 140413, India

ARTICLE INFO:
ABSTRACT

Received:
26
th
Sept.
2026
;
Received
in
revised form: 03
rd
Oct. 2026
;
Accepted:
10
th
Oct.
2026
;
Available
online:
30
th
Oct. 2026.

Keywords:
Phytochemicals,
Nanomedicine, Herbal medicine,
Nanocarriers, Phytosomes,
Bioavailability, Targeted delivery,
Quality by design.

DOI:
https://doi.org/10.61280/5000mf06

*Corresponding
Author:
Abhishek
Tripathi

Email:
25ypd50008@cuchd.in

Natural
products
are
a
rich
source
of
drug-like
phytochemicals;
however,
the
clinical
success
of
promising
candidates
has
been
hampered by issues such as insolubility, instability, rapid metabolism,
limited
tissue
distribution,
and
variation.
Systems
designed
for
drug
delivery can tackle such problems by improving dispersion, protecting
labile phytochemicals from degradation, customizing release kinetics,
and
changing
membrane
interactions.
We
review
lipid
carriers,
liposomes, phytosomes, solid lipid nanoparticles, nanostructured lipid
carriers,
polymeric
nanoparticles,
nanoemulsions,
micelles,
nanocrystals,
proteinaceous
nanoparticles,
and
some
hybrid
systems
for the delivery of phytopharmaceuticals. The original article searches
PubMed/MEDLINE,
ScienceDirect,
Scopus-indexed
articles,
and
Google
Scholar.
None
of
the
search
archives
were
exported
for
verification;
thus,
there
is
no
documented
date
for
the
last
search
undertaken,
no
deduplication
report,
no
documentation
of
screening
by
an
independent
reviewer,
and
the
PRISMA
diagram
numbers
cannot be verified. The unverified number of studies are not presented
as systematic-review results in this updated article for these reasons.
This
review
holds
the
most
studied
phytochemicals
of
curcumin,
resveratrol,
quercetin,
berberine,
epigallocatechin
gallate,
and
silymarin, as the limitations to their delivery have been most clearly
defined
here.
Many
formulation
studies
show
enhancement
of
properties such as perceived solubility, stability, release properties, or
pharmacokinetic
parameters;
however,
they
are
very
dependent
on
formulation, dose, route, model, and comparison. Better delivery does
not
automatically
demonstrate
clinical
effectiveness.
There
is
insufficient
pharmacokinetic
profile
data,
incomplete
quality
attributes,
scale-up
issues
or
challenges,
carrier
toxicity,
and
fewer
well-controlled
clinical
studies.
Our
product-by-product
solution
encompasses
botanical
verification,
chemical
fingerprinting,
quality-
by-design
formulation,
orthogonal
characterization,
case-specific
safety
evaluation,
and
controlled
clinical
testing
when
proper.
Nanocarriers play a prominent role in the development of botanical

Copyright:
©
Author
2026
by
the
Author.
International
Journal
of
Pharmaceutical
Research
and
Medicinal
Plants
Published
by
Informative Journals
(Jadoun Science Publishing Group India). This article is an open access article distributed under the terms and conditions
of the CC BY-NC-ND 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/)
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 27

medicines;
however,
they
are
NOT
considered
a
basis
for
efficacy
claims in and of themselves. Thus, the conclusions that may be drawn
from the assessment of a drug delivery system should be equal with
the level of quality and maturity of the data available.

1. INTRODUCTION

Medicinal
plants
have
informed
health
practices
in
Ayurveda,
Traditional
Chinese
Medicine,
Unani,
and
Indigenous
systems,
and
are
an
important
source
of
pharmacologically
active
molecules.
Contemporary
phytopharmacology
seeks
to
identify
the
active
constituents,
understand
the
mechanisms,
and
establish
reproducible dosage forms. Botanical preparations are chemically complex; activity can arise from a single
molecule,
multiple
constituents,
metabolites,
or
interactions
between
constituents.
This
complexity
is
valuable but makes dose definition, quality control, and the interpretation of clinical outcomes challenging
[1-8]. Many phytochemicals face delivery barriers. Hydrophobic compounds, such as curcumin, resveratrol,
and
quercetin,
have
limited
aqueous
solubility;
some
are
unstable
under
light,
oxygen,
pH,
or
enzymatic
exposure, and rapid conjugation or efflux may limit systemic exposure. Highly polar constituents may not
cross lipid membranes. A conventional extract may vary with species identity, cultivar, geography, harvest,
storage, extraction solvent, and processing [9-16].

Nanomedicine
provides
formulation
approaches
that
can
protect
compounds,
improve
dispersion,
alter
release, and interact with barriers. The carrier itself does not confer pharmacological activity; it changes the
exposure profile and may introduce new risks. The question is not whether a nanoformulation is smaller, but
whether
a
defined
formulation
offers
a
meaningful,
reproducible,
and
safe
improvement
on
a
suitable
comparator [17-24]. This review connects traditional botanical medicines with modern carrier engineering.
Carrier classes are evaluated, phytochemical
examples are discussed, along with analytical and biological
evidence,
clinical
translation,
safety,
and
regulatory
needs.
Findings
are
described
according
to
evidence
level, and preclinical signals are not treated as human efficacy.

2. REVIEW OBJECTIVES AND QUESTIONS

This
review
aimed
to
respond
to
the
following
questions:
(i)
what
carrier
systems
are
used
for
phytochemicals;
(ii)
what
formulation
mechanisms
can
enhance
stability,
absorption,
and
targeting
properties;
(iii)
which
compounds
and
therapeutic
areas
are
considered
the
most
promising;
(iv)
what
preclinical and clinical evidence can support the translation from in vitro and animal studies; and (v) what
quality, safety, and regulatory issues need to be addressed before clinical applications.

3. MATERIALS AND METHODS

3.1 Review design

This
article
was
designed
as
a
critical
narrative
review
with
a
structured
approach
to
literature
identification
and
synthesis
.
Its
purpose
was
to
examine
phytochemical
nanocarrier
technologies,
representative bioactive compounds, reported formulation outcomes, and barriers to clinical translation. The
review does not claim to be a systematic review or meta-analysis because a complete reproducibility record
was not available, including final database search histories, exported records, deduplication files, screening
decisions, and study-level extraction sheets. Accordingly, the findings are presented as a structured critical
synthesis
rather
than
as
a
quantitative
estimate
of
the
literature.
The
review
focuses
on
the
strength
and
limitations
of
the
available
evidence
and
distinguishes
physicochemical,
in
vitro,
animal,
and
human
findings. It does not treat improvements in formulation characteristics or preclinical outcomes as evidence of
clinical effectiveness.

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 28

3.2 Information sources and search concepts

The initial literature search drew on PubMed/MEDLINE, ScienceDirect, Scopus-indexed publications, and
Google
Scholar.
Reference-list
screening
and
searches
of
authoritative
regulatory
or
guidance
documents
were used to show added relevant material.

Search
concepts
combined
terms
for
phytochemicals
and
botanical
medicines
with
terms
for
nanocarrier-
based delivery systems. Phytochemical and botanical terms included
phytochemicals
,
plant extract
,
herbal
medicine
,
curcumin
,
resveratrol
,
quercetin
,
berberine
,
silymarin
, and
epigallocatechin gallate
. These terms
were combined with delivery-related terms, including
nanocarriers
,
nanoparticles
,
liposomes
,
phytosomes
,
nanoemulsions
,
solid lipid nanoparticles
,
nanostructured lipid carriers
,
polymeric nanoparticles
,
micelles
,
nanocrystals
,
vesicles
,
targeting
, and
bioavailability
.

Because the exact database-specific search strings and final search dates from the first work were not kept,
this review does not present the search process as fully reproducible or exhaustive. The literature was used to
show recurring
carrier strategies, representative phytochemicals, commonly reported outcomes, and major
translational limitations.

3.3 Scope and eligibility of the literature considered

The synthesis considered peer-reviewed original research, review articles used for contextual background and
citation
tracking,
human
clinical
studies,
and
official
guidance
relevant
to
nanomaterial-containing
medicines. Priority was
given to
literature
addressing plant-derived bioactives and nanocarrier systems
in
relation
to
formulation
characteristics,
stability,
release,
absorption,
pharmacokinetics,
biodistribution,
biological
activity,
safety,
manufacturing,
or
clinical
translation.
Studies
focused
exclusively
on
synthetic
drugs
or
non-medicinal
materials
were
not
central
to
the
review
unless
they
provided
directly
relevant
information on carrier design, characterization, safety assessment, or regulatory considerations applicable to
phytochemical formulations. Review articles were used to contextualize the field and find relevant primary
studies; they were not treated as independent experimental evidence.

3.4 Evidence organization and critical synthesis

The literature was organized according to carrier architecture, phytochemical class, therapeutic application,
and stage of evidence. Evidence was categorized as physicochemical, in vitro, animal, human, or marketed-
product
evidence
where
applicable.
The
synthesis
considered
botanical
or
compound
identity,
carrier
composition,
particle size, and disparity when reported, encapsulation or loading, route of administration,
comparator, biological
outcome, safety
information, and stated limitations. Given the marked diversity
of
carrier systems, active compounds, study models, routes of administration, doses, analytical methods, and
outcome
measures,
a
pooled
quantitative
analysis
was
not
proper.
Instead,
the
review
critically
examines
whether reported formulation advantages are supported by suitable comparators and whether they provide a
plausible basis for later translational development.

3.5 Interpretation of evidence and methodological limitations

The review applies an evidence-level framework to avoid equating laboratory or animal findings with clinical
benefit. Improvements in particle size, encapsulation efficiency, stability, release behaviour, cellular uptake,
or
pharmacokinetic
exposure
are
interpreted
as
formulation-related
findings.
Such
outcomes
may
support
further development but do not independently prove therapeutic superiority, safety, or clinical efficacy. The
review has several limitations. A fully reproducible systematic-review process would require a dated search
update,
database-specific
search
strings,
exported
records,
documented
deduplication
procedures,
independent
title-and-abstract
and
full-text
screening,
reasons
for
exclusion,
and
a
PRISMA
2020
flow
diagram based on an auditable screening record. Study-level risk-of-bias assessment would also be needed,
using design-appropriate tools such as RoB 2 for randomized clinical trials and SYRCLE for animal studies.

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 29

Because these materials were not available for the present review, the findings should be interpreted as a
critical narrative appraisal of the field rather than as a systematic estimate of the evidence base.

4. RESULTS

4.1 Overview of the evidence landscape

In the evidence configuration described many of the considered manuscripts are focused on formulations and
preclinical
findings.
Indeed,
the
triple
combination
of
curcumin,
resveratrol
and
quercetin
is
mentioned
several
times
due
to
its
reported
insufficient
aqueous
solubility,
chemical
instability,
or
rapid
metabolic
transformation. Berberine, epigallocatechin gallate, silymarin and other phytochemicals are also mentioned in
the
context
of
different
carriers.
In
this
regard,
encapsulation
is
proposed
to
improve
the
content
of
the
entrapped substance, decrease its degradation rate, change the release properties, or enhance the exposure of
the target tissue. These are several aspects, and the cumulative evidence grade should not be confused by the
presence of any single positive result. A higher encapsulation efficiency, reduced particle size, or increased in
vitro efficacy message cannot be used as sufficient proof of a compound’s superiority.

One of the key conclusions of this evidence synthesis is that the number of studies with potentially valuable
formulations significantly exceeds the quantity of positive clinical findings. Preclinical and physicochemical
data are represented by a substantial number of articles, while human evidence is mostly ranked as moderate
or low due to the absence of consistent control groups. Animal studies are even more challenging to analyze
due
to
the
wide
range
of
interventions
and
study
designs
used
in
different
research
groups.
Therefore,
comparative efficacy claims are mostly based on head-to-head trials, which directly compare the same test
substance
or
combination.
Indeed,
comparing
the
same
dose
of
the
entrapped
compound,
the
free
drug
formulation
(if
applicable)
and
carrier-alone
is
the
optimal
strategy
to
prove
the
value
of
a
new
delivery
system.
For
pharmacokinetic
claims,
the
use
of
validated
and
consistent
analytical
techniques
is
critical,
while the inclusion of clinically relevant efficacy endpoints requires researchers to design a suitable control
group. At the same time, the current state of the analyzed body of evidence does not allow for conducting
large-scale quantitative analysis or producing a single grade for individual carriers. This is due to the lack of
access to individual participant data and the completion of the risk of bias assessment by the original authors.

Table 1:
Evidence domains used to compare phytochemical carrier studies.

Evidence domain

Common reported endpoint

Interpretive caution

Physicochemical

Particle
size,
PDI,
zeta
potential,
loading,
encapsulation efficiency

Values
depend
on
method,
medium,
dilution,
and
storage;
a
single
size
value
is
insufficient.

In vitro delivery

Dissolution,
release,
cell
uptake,
cytotoxicity,
antioxidant assays

Assay
interference
and
non-
physiological
concentrations
can exaggerate these effects.

Animal studies

AUC/Cmax, tissue distribution,
disease scores, histology

Species,
routes,
model,
and
dose
may
not
predict
human
benefit.

Human studies

Pharmacokinetics,
tolerability,
symptoms, biomarkers, clinical
endpoints

Small
sample
sizes
and
surrogate
outcomes
may
not
show effectiveness.

The table summarizes commonly reported endpoints and the main cautions needed for interpretation; it is a
framework for synthesis rather than a claim that every study reported every endpoint.

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 30

4.2 Major nanocarrier systems

4.2.1 Liposomes and related vesicles

Liposomes are phospholipid membranes that can encapsulate hydrophilic molecules in their aqueous cores
and hydrophobic ones in the membrane itself. They can be made from various phospholipids, cholesterol,
PEG, ligands, and other materials depending on the desired properties. Phytochemicals can be enclosed in
liposomes to target certain tissues and provide therapeutic benefits. Their advantages include protection of
the payload and altered biodistribution, while the challenges are leakage, lipid auto-oxidation or hydrolysis,
stability, and cost [49–58].

Niosomes,
transfersomes,
and
ethosomes
are
like
liposomes
but
have
several
types
of
surfactants
or
can
deform
under
pressure.
Transfersomes
and
ethosomes
are
particularly
interesting
for
the
enhanced
penetration
of
their
contents
into
the
skin
layers.
However,
such
data
require
other
validation
through
permeation studies, as well as evaluation of irritation and systemic exposure if applicable [59–64].

4.2.2 Phytosomes and phospholipid complexes

Phytosomes
can
be
described
as
association
products
of
plant-derived
material
and
phospholipids,
not
aqueous-core liposomes. The involvement of hydrogen bonding and other interactions may contribute to their
enhanced
partitioning
and
absorption
of
specific
polyphenols
such
as
curcumin,
silybin
or
grape-seed
polyphenols.
Available
phytosomal
products
on
the
market
cannot
prove
their
similarity
in
terms
of
the
content of botanical ingredients or ratio of ligand/phospholipid, technological aspects, and clinical data [65–
72].

4.2.3 Solid lipid nanoparticles and nanostructured lipid carriers

Solid lipid
nanoparticles (SLNs) are
formed from
a solid lipid
matrix, while nanostructured lipid
carriers
(NLCs) are composed of solid and liquid lipids, allowing the formation of a less ordered matrix having a
higher amount of active compound and reducing its expulsion during storage. The use of SLNs and NLCs for
the
delivery
of
lipophilic
phytochemicals
can
provide
protection
to
the
active
compounds
and
can
be
developed
in
oral,
topical
or
parenteral
formulations.
However,
the
potential
limitations
include
drug
expulsion due to crystal growth, polymorphic transformations, tolerability of surfactants used, lipid digestion
and variable release rates in biological fluids [73–80].

4.2.4 Polymeric nanoparticles and nanocapsules

Polymeric carriers can be made from biodegradable polymers, such as poly (lactic-co-glycolic acid) (PLGA),
polylactide, chitosan, alginate, gelatin, or other natural and synthetic polymers. Nanocapsules can generate a
reservoir-type structure, while nanospheres have the active principle dispersed within the polymer matrix.
Properties of surface chemistry, polymer molecular weight, degradation rate, and residual solvent should be
considered. The fact that the polymer is biodegradable is not dispensable for the comprehensive evaluation of
the
product
and
its
toxicity;
thus,
characterization
of
degradation
products,
immunological
response
and
repeated-dose toxicity studies are needed [81-90].

4.2.5 Nanoemulsions, micelles and nanocrystals

Nanoemulsions are kinetically stable dispersions of oil in water stabilized by surfactants; they may enhance
the plain solubilization and gastrointestinal dispersion of hydrophobic constituents. Micelles can solubilize
hydrophobic molecules
within hydrophobic domains
and may be useful
when the unperturbed compound
precipitates
out
of
aqueous
media.
Nanocrystals
increase
the
surface
area
and
thus
the
dissolution
rate
without
requiring
a
large
carrier
mass.
The
technologies
are
not
interchangeable:
a
nanoemulsion
is
not
necessarily thermodynamically stable, and increased dissolution does not always lead to increased absorption
[91–99].

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 31

4.2.6 Protein-based, polysaccharide and hybrid systems

Albumin,
casein,
zein,
gelatin
and
other
food-compatible
proteins
can
interact
with
plant
bioactives
via
hydrophobic
interactions,
hydrogen
bonding,
or
electrostatic
forces.
Polysaccharides
such
as
chitosan,
alginate
and
pectin
can
provide
mucoadhesion,
pH
sensitivity
or
protective
matrices.
Hybrid
systems
are
combinations of materials to tailor loading, stability, or triggered release. Their performance is influenced by
ionic strength, digestive enzymes, protein corona formation, presence of food components and batch-to-batch
variations in materials [100–108].

4.2.7 Inorganic, metallic, and biomimetic systems

Gold, silver, silica, iron oxide, and other inorganic nanomaterials have been explored as carriers, imaging
agents, or components of multifunctional systems. Their long persistence, surface reactivity and potential for
accumulation make them different from many biodegradable organic carriers. Green synthesis using plant
extracts
may
provide
reducing
or
capping
molecules,
but
plant-mediated
synthesis
is
not
guaranteed
to
produce reproducible, pure, or safe materials. Exosomes and cell-membrane-inspired systems are promising
carriers,
but
require
careful
characterization
of
sources,
scalable
isolation
methods,
and
control
of
the
biological cargo [109–116].

Table 2:
Comparison of major carrier platforms used for phytochemical delivery.

Carrier class

Potential advantage

Key limitations/tests

Liposomes/vesicles

Encapsulate
polar
and
nonpolar
compounds; modifiable surface

Leakage,
oxidation,
storage
stability, sterilization and scale-up

Phytosomes

Phospholipid
complex
may
improve
partitioning
and
absorption

Must
confirm
complex
formation,
composition,
and
product-specific
clinical evidence

SLN / NLC

Lipid
compatibility;
protect
lipophilic actives

Polymorphism,
drug
expulsion,
digestion, and surfactant effects

Polymeric nanoparticles

Tunable
degradation
and
release;
surface
functionalization

Residual
solvent,
polymer
impurities, degradation, and repeat-
dose toxicity

Nanoemulsions/micelles

Improve
dispersion
and
clear
solubilization

Dilution/food effects, precipitation,
surfactant burden, and stability

Protein/polysaccharide

Biocompatible
matrices;
mucoadhesion or pH response

Batch
variability,
digestion,
allergenicity, and ionic sensitivity

Inorganic / hybrid

Imaging,
external
responsiveness,
multifunctionality

Persistence,
biodistribution,
clearance,
and
long-term
toxicology

Carrier
selection
should
be
guided
by
the
compound’s
chemistry,
route,
target
tissue,
manufacturing
constraints, and safety profile rather than particle size alone [17, 23, 49, 65, 73, 81, 91, 100, 109].

4.3 Representative phytochemicals and formulation rationale

4.3.1 Curcumin

Curcumin,
an
active
part
of
Curcuma
longa,
has
been
subject
to
extensive
investigation
for
its
anti-
inflammatory and antioxidant activity. However, the low aqueous solubility, chemical
stability, and rapid
metabolism
limit
the
oral
bioavailability.
Various
nanoparticle
systems
such
as
liposomes,
polymeric
nanoparticles, lipid-based carriers, micelles, nanocrystals, and phytosomes have been explored to improve the

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 32

delivery of curcumin. A systematic review of the literature focusing on the nanoparticle delivery of curcumin
highlighted the need to differentiate between the enhancement of pharmacokinetic properties and antitumor
efficacy
and
to
compare
the
performance
of
different
formulations
[117–121].
In
addition,
curcumin-
containing formulations require a chemical characterization of curcuminoids and their degradation products,
and
only
formulations
that
have
proven
efficacy
in
a
controlled
clinical
study
of
humans
can
make
pharmacological claims.

4.3.2 Resveratrol

Resveratrol,
a
stilbenoid
found
in
grapes
and
several
other
plant
species,
has
poor
aqueous
solubility,
undergoes
photoisomerization,
oxidation,
and
rapid
metabolic
conversion.
Encapsulation
in
liposomes,
polymeric
nanoparticles,
lipid
nanocarriers,
micelles,
nanoemulsions,
and
protein
carriers
have
been
investigated.
Recent
reviews
highlight
the
importance
of
optimizing
formulations
to
improve
pharmacokinetic parameters and underscore the need for further investigations of the therapeutic potential
and safety of resveratrol in vivo [122–126].

4.3.3 Quercetin and other flavonoids

Quercetin is associated with low aqueous solubility and undergoes extensive metabolism. Thus, lipid-based
formulations, polymeric systems, cyclodextrin complexes, micelles, and nanoemulsions have been explored
for
the
delivery
of
this
flavonoid.
Similarly,
other
flavonoids
including
EGCG,
naringenin,
genistein,
kaempferol,
and
fisetin
have
been
studied;
each
exhibits
different
stability
and
metabolic
profiles,
and
therefore, a flavonoid delivery platform cannot be extrapolated from one compound to another [127–132].

4.3.4 Berberine, silymarin and other botanical actives

Berberine is an isoquinoline alkaloid that is subject to limited oral bioavailability due to its poor absorption
and extensive metabolism and/or excretion processes. Thus, nanocarriers reviewed by the authors of [129]
are
lipids,
polymeric
particles,
and
other
systems
designed
to
improve
the
pharmacokinetics
and
tissue
distribution of the drug. At the same time, the study [129] notes that silymarin/silybin, artemisinin, celastrol,
boswellic acids, andrographolide, and other phytochemicals have also been used to deliver various natural
products. However, each of these compounds requires a detailed description of the chemical markers and a
thorough assessment of interactions and safety data; thus, an isolated molecule of a drug is not identical to a
complex of a natural product [133–138].

Table 3:
Commonly investigated phytochemicals and their formulation rationale.

Phytochemical

Botanical source
(example)

Main formulation
challenge

Platforms explored

Curcumin

Curcuma longa

Poor aqueous solubility;
rapid metabolism

Phytosomes, liposomes,
polymeric and lipid
nanoparticles

Resveratrol

Vitis vinifera and others

Solubility,
photoisomerization,
oxidation

Liposomes, micelles,
lipid/polymeric particles

Quercetin

Many fruits and
medicinal plants

Low solubility;
extensive metabolism

Lipid carriers, polymeric
systems, cyclodextrins

Berberine

Berberis spp., Coptis
spp.

Low systemic exposure;
transporter/metabolic
effects

Polymeric and lipid-based
nanocarriers

EGCG

Camellia sinensis

Chemical instability and
limited exposure

Liposomes, polymeric
and protein-based carriers

Silybin

Silybum marianum

Low solubility and
variable absorption

Phytosomes, lipid
carriers, nanoparticles

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 33

These examples reflect research directions and do not imply equivalent clinical evidence across products or
indications [65–72, 117–138].

4.4 Mechanisms by which carriers may alter delivery

One
of
the
basic
characteristics
of
delivery
carriers
is
the
ability
to
prove
activity
through
their
action,
regardless of the mechanism of action. The mechanism of action of the carrier can differ and include: (i)
enhancement
of
wetting
and
dispersion;
(ii)
protection
of
the
compound
from
hydrolysis,
oxidation,
photolysis
or
metabolic
transformations;
(iii)
regulation
of
the
dissolution
profile;
(iv)
promotion
of
penetration
through
barriers
(epithelial
or
cellular);
(v)
modulation
of
lymphatic
absorption
or
the
reticuloendothelial
system;
(vi)
targeting
of
specific
sites
by
virtue
of
a
ligand,
local
administration,
or
response to a stimulus. In addition to the examples listed, the ability of a carrier to direct the drug to the site
of action varies depending on the formulation and route of administration, and this must be considered when
designing
the
system,
not
taken
for
granted
[139–142].
Such
factors
as
surface
charge,
particle
size
distribution,
shape,
rigidity,
protein
binding,
and
interaction
with
mucin
also
affect
the
properties
of
the
carrier. One should be especially careful about the common assertion that nanoparticles are delivered to the
tumour
via
the
enhanced
permeability
and
retention
effect.
Vascular
permeability
in
humans
is
heterogeneous,
and
nanoparticle
accumulation
in
tumour
tissue
in
preclinical
studies
does
not
always
translate into clinical success. Targeting using targeting ligands can increase cellular uptake but has slight
effect on overall tissue distribution [20–24, 143–147].

Figure 1:
Product-specific development pathway for nano-phytomedicine

Figure 1 The pathway links botanical authentication and chemical fingerprinting with formulation, quality,
and safety testing, and clinical validation. Each stage is a decision gate requiring product-specific evidence;
progression through the pathway should not be assumed.

5. DISCUSSION

The
evidence
supports
nanocarriers
as
enabling
pharmaceutical
technologies
for
selected
phytochemicals
when a defined physicochemical barrier is overcome by a compatible formulation (e.g., improved dissolution
or prevention of degradation). The most convincing arguments begin with a mechanistic problem (such as
poor dissolution or rapid degradation) and show how the exposure variable (relevant to the mechanism) is
changed by the carrier and shows a biological effect at a comparable or clinically relevant dose. Novelty by

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 34

itself is not an outcome. A recurring weakness is an overreliance on in vitro assays and on a single animal
model. Cell-based antioxidants or cytotoxicity assays can give misleading results if the nanoparticle causes
light scattering, fluorescence quenching or adsorption of assay reagents
or non-specific membrane injury.
Blank-carrier
controls,
orthogonal
assays,
and proper analysis of the dose-response
are needed.
Improved
plasma concentrations in animals must be related to unbound concentration at the target site and linked to a
relevant pharmacodynamic endpoint. Positives and negatives should be reported.

Botanical
quality
is
a
fundamental
issue.
Correct
species
identification,
plant
part,
extraction
method,
chromatographic fingerprint, marker compound ranges, contaminants, and stability must be defined before
carrier optimization. A nano formulation may increase exposure not only of desired constituents but also of
contaminants or unwanted constituents. Whole extract delivery raises questions of whether the active cocktail
is stable during manufacturing and storage and whether the carrier preferentially partitions some constituents
and
thereby
changes
the
original
phytochemical
profile
[1–8,65–72].
The
carrier
itself
can
carry
risks.
Cationic surfaces can damage membranes, surfactants can be irritating or disrupt barrier integrity, inorganic
components
can
be
kept
in
tissue
and
polymers,
or
lipids
can
change
degradation
profiles,
immune
recognition, or biodistribution. The safety profile of the free phytochemical cannot be relied on as a surrogate
for
the
final
formulation.
Appropriate
evaluation
would
include
route-relevant
local
tolerance,
systemic
toxicity,
immunogenicity
where
relevant,
reproductive
or
genotoxicity
when
indicated
and
potential
interactions in the relevant population.

Clinical
translation
is
still
the
outstanding
challenge.
Some
phytosomal
and
enhanced-bioavailability
botanical products are available; selected formulation-specific clinical studies are available; nevertheless, a
commercial
label,
small
trial
or
surrogate
biomarker
does
not
constitute
broad
therapeutic
effectiveness.
Human studies should use rigorous randomization, sufficient sample size, pre-specified outcomes, validated
analytical assays, dose justification, clinically relevant comparator, and systematic adverse event reporting. A
conventional
extract
and
nano
formulation
should
be
compared
directly
if
nanotechnology
is
claimed
to
enhance clinical benefit. The next generation of research should focus on quality-by-design, critical quality
attributes, robust scale-up, continuous manufacturing where proper, stability-indicating analytical methods,
realistic
biorelevant
testing,
physiologically
based
pharmacokinetic
modelling
and
early
regulatory
engagement.
AI
and
computational
screening
may
aid
in
prioritizing
carrier
compositions;
however,
predictions
will
need
experimental
verification.
Sustainable
sourcing
and
reduced
solvent
use
are
also
important if a technology to enhance plant-derived medicine is to avoid creating an avoidable environmental
burden.

5.1 Translational evidence and decision points

Table 4:
Suggested stage-gate framework for translating nano-phytomedicines.

Development stage

Minimum evidence package

Decision question

Botanical / compound
definition

Taxonomic authentication,
fingerprint, marker assay,
contaminants, stability

Is the active material
reproducible and adequately
defined?

Formulation optimization

Size distribution, morphology,
loading, release, residuals,
batch variation

Does the carrier solve a defined
limitation?

Preclinical proof

Relevant controls, exposure
measurements, efficacy model,
route-specific toxicology

Does improved delivery
produce a meaningful benefit at
tolerable exposure?

Clinical translation

Human pharmacokinetics, dose

Is the specific product better

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 35

finding, randomized efficacy
trial, safety monitoring

than a suitable comparator?

Manufacturing/lifecycle

Validated process,
specifications, stability, change
control, pharmacovigilance

Can quality and safety be
supported on a scale?

Each stage should be passed using product-specific data; evidence from another compound or carrier cannot
substitute for validation of the candidate formulation [23, 40–48, 148–152].

5.2 Limitations of this review

Several
limitations
affect
interpretation.
The
manuscript
brings
together
a
mix
of
compounds,
carrier
compositions,
routes,
models,
and
outcomes,
which
prevents
a
defensible
quantitative
synthesis
without
defining
a
narrower
question
and
harmonizing
the
data.
The
provided
source
did
not
include
archives
of
search histories, a verified search cutoff, deduplication and screening logs, reasons for full-text exclusion, a
complete PRISMA count record or completed study-level risk-of-bias assessments. Therefore, the revised
manuscript enhances structure and transparency but cannot honestly claim that these reproducibility steps
have
been
completed.
Publication
bias
and
selective
reporting
could
enhance
positive
findings
on
formulation,
while
incomplete
characterizations
make
cross-study
comparisons
unreliable.
Before
submission, a subject librarian or experienced co-author should reproduce the searches independently, verify
eligibility
decisions,
check
the
extracted
data
against
original
reports,
and
confirm
each
risk-of-bias
judgement.

Figure 2:
Overview of carrier classes investigated for phytochemical delivery.

Figure
2
Representative
carrier
families
include
liposomes,
phytosomes,
lipid
nanoparticles,
polymeric
particles, nanoemulsions or micelles, and protein-based or hybrid systems. The diagram is conceptual and
does not imply that one platform is universally superior.

6. FUTURE PERSPECTIVES

Future
development
should
be
focused
on
clinically
relevant
rather
than
purely
technological
advances,
including oral carriers that are resistant to digestion and deliver their payloads at a desired site within the
intestine, topical carriers with characterized skin deposition and tolerability, inhalation or parenteral systems
with
strict
control
over
sterility,
endotoxin
and
biodistribution,
or
disease-targeted
platforms
with

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 36

reproducible target engagement. Combination delivery of multiple phytochemicals may be a useful strategy,
but it increases the burden of characterizing the components and their interactions.

A pragmatic translation strategy would be to choose a small number of well-characterized phytochemicals
with an established exposure limitation, use a carrier with a compelling safety and manufacturing rationale
and
analytical
comparability
between
batches,
and
continue
through
pharmacokinetic
and
dose-ranging
investigations. Traditional medicines may guide compound
choice and therapeutic domain,
while modern
chemistry, pharmacology, and clinical science define identity, quality, safety, and efficacy.

7. CONCLUSION

Novel carrier systems stand for a viable link between traditional botanical medicine and nanomedicine by
addressing selected delivery limitations and challenges that phytochemicals face. Liposomes, phytosomes,
lipid
and
polymeric
nanoparticles,
nanoemulsions,
micelles
and
other
systems
can
help
to
improve
dispersion,
protect
unstable
compounds,
alter
release
and,
in
some
cases,
boost
exposure
or
biological
activity. The extent and importance of these benefits are compound-, carrier-, route- and product-specific.
Preclinical improvements should not be extrapolated to proof of efficacy in humans, and carrier-related risks
need
to
be
assessed
independently
of
the
botanical
ingredient.
Advancement
requires
botanical
authentication, chemical fingerprinting, thorough characterization, reproducible manufacturing, appropriate
toxicology,
rigorous
human
studies,
and
transparent
regulatory
evaluation.
The
field
will
realize
its
true
potential when nanotechnology is used to solve a defined delivery problem and when every claim is backed
up by evidence for the final formulation.

REFERENCES

  1. 1.
    World Health Organization. WHO traditional medicine strategy: 2014–2023. Geneva: WHO; 2013.
  2. 2.
    Atanasov
    AG,
    Waltenberger
    B,
    Pferschy-Wenzig
    EM,
    et
    al.
    Discovery
    and
    resupply
    of
    pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582-
    1614. doi:10.1016/j.biotechadv.2015.08.001.
  3. 3.
    Newman
    DJ,
    Cragg
    GM.
    Natural
    products
    as
    sources
    of
    new
    drugs
    over
    the
    four
    decades
    from
    01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803. doi:10.1021/acs.jnatprod.9b01285.
  4. 4.
    Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery.
    Environ Health Perspect. 2001;109 Suppl 1:69-75. doi:10.1289/ehp.01109s169.
  5. 5.
    Rates
    SMK.
    Plants
    as
    source
    of
    drugs.
    Toxicon.
    2001;39(5):603-613.
    doi:10.1016/S0041-
    0101(00)00154-9.
  6. 6.
    Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science.
    2009;325(5937):161-165. doi:10.1126/science.1168243.
  7. 7.
    Pan SY, Zhou SF, Gao SH, et al. New perspectives on how to discover drugs from herbal medicines:
    CAM's
    outstanding
    contribution
    to
    modern
    therapeutics.
    Evid
    Based
    Complement
    Alternat
    Med.
    2013;2013:627375. doi:10.1155/2013/627375.
  8. 8.
    Booker
    A,
    Johnston
    D,
    Heinrich
    M.
    Value
    chains
    of
    herbal
    medicines—research
    needs
    and
    key
    challenges
    in
    the
    context
    of
    ethnopharmacology.
    J
    Ethnopharmacol.
    2012;140(3):624-633.
    doi:10.1016/j.jep.2012.01.039.
  9. 9.
    Chavda
    VP,
    Vihol
    D,
    Mehta
    B,
    et
    al.
    Phytochemical-loaded
    liposomes
    for
    anticancer
    therapy:
    an
    updated review. Nanomedicine (Lond). 2022;17(8):547-568. doi:10.2217/nnm-2021-0463.
  10. 10.
    Singh M, Devi S, Rana VS, et al. Delivery of phytochemicals by liposome cargos: recent progress,
    challenges,
    and
    opportunities.
    J
    Microencapsul.
    2019;36(3):215-235.
    doi:10.1080/02652048.2019.1617361.
  11. 11.
    Applications
    of
    Nanocarriers
    as
    Drug
    Delivery
    Vehicles
    for
    Active
    Phytoconstituents.
    Curr
    Pharm
    Des. 2020. doi:10.2174/1381612826666200610111013.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 37
  1. 12.
    Chauhan
    D,
    Yadav
    PK,
    Sultana
    N,
    et
    al.
    Advancements
    in
    nanotechnology
    for
    the
    delivery
    of
    phytochemicals. J Integr Med. 2024;22(4):385-398. doi:10.1016/j.joim.2024.04.005.
  2. 13.
    Barani M, Bilal M, Rahdar A, et al. Phytosomes as innovative delivery systems for phytochemicals: a
    comprehensive
    review
    of
    literature.
    Int
    J
    Nanomedicine.
    2021;16:6983-7022.
    doi:10.2147/IJN.S318416.
  3. 14.
    Li C, Wang Z, Lei H, Zhang D. Recent progress in nanotechnology-based drug carriers for resveratrol
    delivery. Drug Deliv. 2023;30(1):2174206. doi:10.1080/10717544.2023.2174206.
  4. 15.
    Santos AC, Pereira I, Pereira-Silva M, et al. Nanocarriers for resveratrol delivery: impact on stability
    and solubility concerns. Trends Food Sci Technol. 2019;91:483-497. doi:10.1016/j.tifs.2019.07.048.
  5. 16.
    Homayoonfal
    M,
    Aminianfar
    A,
    Asemi
    Z,
    Yousefi
    B.
    Application
    of
    nanoparticles
    for
    efficient
    delivery
    of
    quercetin
    in
    cancer
    cells.
    Curr
    Med
    Chem.
    2024;31(9):1107-1141.
    doi:10.2174/0929867330666230301121611.
  6. 17.
    Silvestre F, Santos C, Silva V, et al. Pharmacokinetics of curcumin delivered by nanoparticles and the
    relationship
    with
    antitumor efficacy:
    a systematic review. Pharmaceuticals
    (Basel). 2023;16(7):943.
    doi:10.3390/ph16070943.
  7. 18.
    Li S, Yuan W, Deng G, Wang P, Yang P, Aggarwal BB. Chemical composition and product quality
    control
    of
    turmeric
    (Curcuma
    longa
    L.).
    Pharm
    Crops.
    2011;2:28-54.
    doi:10.2174/2210290601102010028.
  8. 19.
    Anand
    Anubhav,
    Preety
    G,
    Smriti
    O.
    Application
    of
    nanotechnology
    for
    herbal
    medicine
    development:
    a
    review.
    Lett
    Drug
    Des
    Discov.
    2024;21(8).
    doi:10.2174/1570180820666230308105723.
  9. 20.
    Khan
    MJ,
    Hafeez
    A,
    Siddiqui
    MA.
    Nanocarrier
    based
    delivery
    of
    berberine:
    a
    critical
    review
    on
    pharmaceutical
    and
    preclinical
    characteristics
    of
    the
    bioactive.
    Curr
    Pharm
    Biotechnol.
    2023;24(11):1449-1464. doi:10.2174/1389201024666230112141330.
  10. 21.
    Chopra H, Bibi S, Singh I, et
    al.
    Emerging trends in
    the delivery of resveratrol by nanostructures:
    applications
    of
    nanotechnology
    in
    life
    sciences.
    J
    Nanomater.
    2022;2022:3083728.
    doi:10.1155/2022/3083728.
  11. 22.
    Song
    Y,
    Zhang
    J,
    Zhu
    L,
    Zhang
    H,
    Wu
    G,
    Liu
    T.
    Recent
    advances
    in
    nanodelivery
    systems
    of
    resveratrol
    and
    their
    biomedical
    and
    food
    applications:
    a
    review.
    Food
    Funct.
    2024;15:8629-8643.
    doi:10.1039/D3FO03892K.
  12. 23.
    FDA.
    Considering
    whether
    an
    FDA-regulated
    product
    involves
    the
    application
    of
    nanotechnology:
    guidance for industry. Silver Spring (MD): US Food and Drug Administration; 2014.
  13. 24.
    US
    Food
    and
    Drug
    Administration.
    Drug
    products,
    including
    biological
    products,
    that
    hold
    nanomaterials: guidance for industry. Silver Spring (MD): FDA; 2022.
  14. 25.
    European
    Medicines
    Agency.
    Reflection
    paper
    on
    nanotechnology-based
    medicinal
    products
    for
    human use. London: EMA; 2006.
  15. 26.
    European
    Medicines
    Agency.
    Reflection
    paper
    on
    the
    data
    requirements
    for
    intravenous
    liposomal
    products developed with reference to an innovator liposomal product. London: EMA; 2013.
  16. 27.
    International Organization for Standardization. ISO/TR 13014:2012 Nanotechnologies—guidance on
    physico-chemical
    characterization
    of
    engineered
    nanoscale
    materials
    for
    toxicologic
    assessment.
    Geneva: ISO; 2012.
  17. 28.
    International Organization for Standardization. ISO 21363:2020 Nanotechnologies—measurements of
    particle size and shape distributions by transmission electron microscopy. Geneva: ISO; 2020.
  18. 29.
    International Organization for Standardization. ISO 22412:2017 Particle size analysis—dynamic light
    scattering (DLS). Geneva: ISO; 2017.
  19. 30.
    International
    Organization
    for
    Standardization.
    ISO
    10993-1:2018
    Biological
    evaluation
    of
    medical
    devices—part 1: evaluation and testing within a risk management process. Geneva: ISO; 2018.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 38
  1. 31.
    Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision
    nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-124. doi:10.1038/s41573-020-
    0090-8.
  2. 32.
    Shi
    J,
    Kantoff
    PW,
    Wooster
    R,
    Farokhzad
    OC.
    Cancer
    nanomedicine:
    progress,
    challenges,
    and
    opportunities. Nat Rev Cancer. 2017;17(1):20-37. doi:10.1038/nrc.2016.108.
  3. 33.
    Peer
    D,
    Karp
    JM,
    Hong
    S,
    Farokhzad
    OC,
    Margalit
    R,
    Langer
    R.
    Nanocarriers
    as
    an
    emerging
    platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760. doi:10.1038/nnano.2007.387.
  4. 34.
    Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to
    drug delivery. Nat Biotechnol. 2015;33(9):941-951. doi:10.1038/nbt.3330.
  5. 35.
    Anselmo
    AC,
    Mitragotri
    S.
    Nanoparticles
    in
    the
    clinic.
    Bioeng
    Transl
    Med.
    2016;1(1):10-29.
    doi:10.1002/btm2.10003.
  6. 36.
    Anselmo
    AC,
    Mitragotri
    S.
    Nanoparticles
    in
    the
    clinic:
    an
    update.
    Bioeng
    Transl
    Med.
    2019;4(3):e10143. doi:10.1002/btm2.10143.
  7. 37.
    Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of
    FDA-approved
    materials
    and
    clinical
    trials
    to
    date.
    Pharm
    Res.
    2016;33(10):2373-2387.
    doi:10.1007/s11095-016-195 nanoparticle.
  8. 38.
    Ventola
    CL.
    Progress
    in
    nanomedicine:
    approved
    and
    investigational
    nanodrugs.
    P
    T.
    2017;42(12):742-755.
  9. 39.
    Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater.
    2016;1:16014. doi:10.1038/natrevmats.2016.14.
  10. 40.
    Danhier
    F,
    Feron
    O,
    Préat
    V.
    To
    exploit
    the
    tumor
    microenvironment:
    passive
    and
    active
    tumor
    targeting
    of
    nanocarriers
    for
    anti-cancer
    drug
    delivery.
    J
    Control
    Release.
    2010;148(2):135-146.
    doi:10.1016/j.jconrel.2010.08.027.
  11. 41.
    Jain
    RK,
    Stylianopoulos
    T.
    Delivering
    nanomedicine
    to
    solid
    tumors.
    Nat
    Rev
    Clin
    Oncol.
    2010;7(11):653-664. doi:10.1038/nrclinonc.2010.139.
  12. 42.
    Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in
    macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284. doi:10.1016/S0168-
    3659(99)00248-5.
  13. 43.
    Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress, and challenges towards targeted delivery
    of cancer therapeutics. Nat Commun. 2018;9:1410. doi:10.1038/s41467-018-03705-y.
  14. 44.
    Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems.
    Pharmacol Rep. 2012;64(5):1020-1037. doi:10.1016/S1734-1140(12)70901-5.
  15. 45.
    Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv
    Drug Deliv Rev. 2013;65(1):36-48. doi:10.1016/j.addr.2012.09.037.
  16. 46.
    Sercombe
    L,
    Veerati
    T,
    Moheimani
    F,
    Wu
    SY,
    Sood
    AK,
    Hua
    S.
    Advances
    and
    challenges
    of
    liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.00286.
  17. 47.
    Akbarzadeh
    A,
    Rezaei-Sadabady
    R,
    Davaran
    S,
    et
    al.
    Liposome:
    classification,
    preparation,
    and
    applications. Nanoscale Res Lett. 2013;8:102. doi:10.1186/1556-276X-8-102.
  18. 48.
    Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975-999.
    doi:10.2147/IJN.S68861.
  19. 49.
    Immordino
    ML,
    Dosio
    F,
    Cattel
    L.
    Stealth
    liposomes:
    review
    of
    the
    basic
    science,
    rationale,
    and
    clinical applications, existing, and potential. Int J Nanomedicine. 2006;1(3):297-315.
  20. 50.
    Bulbake
    U,
    Doppalapudi
    S,
    Kommineni
    N,
    Khan
    W.
    Liposomal
    formulations
    in
    clinical
    use:
    an
    updated review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012.
  21. 51.
    Edwards
    K,
    Baeumner
    A.
    Liposomes
    in
    analyses.
    Talanta.
    2006;68(5):1432-1441.
    doi:10.1016/j.talanta.2005.08.041.
  22. 52.
    Riaz M. Liposomes preparation methods. Pak J Pharm Sci. 1996;9(1):65-77.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 39
  1. 53.
    Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol.
    1995;13(12):527-537. doi:10.1016/S0167-7799(00)89017-4.
  2. 54.
    Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen
    phospholipids. J Mol Biol. 1965;13(1):238-252. doi:10.1016/S0022-2836(65)80093-6.
  3. 55.
    New RRC, editor. Liposomes: a practical approach. Oxford: IRL Press; 1990.
  4. 56.
    Risselada HJ, Marrink SJ. The molecular face of lipids. Nat Rev Mol Cell Biol. 2009;10(10):739-750.
    doi:10.1038/nrm2745.
  5. 57.
    Gregoriadis G. Liposome technology. 3rd ed. Boca Raton: CRC Press; 2006.
  6. 58.
    Singh A, Neupane YR, Panda BP, Kohli K. Lipid-based nanocarriers for drug delivery: a review. J
    Drug Deliv Sci Technol. 2020;56:101549. doi:10.1016/j.jddst.2020.101549.
  7. 59.
    Barani
    M,
    Sangiovanni
    E,
    Angarano
    M,
    et
    al.
    Phytosomes
    as
    innovative
    delivery
    systems
    for
    phytochemicals:
    a
    comprehensive
    review
    of
    literature.
    Int
    J
    Nanomedicine.
    2021;16:6983-7022.
    doi:10.2147/IJN.S318416.
  8. 60.
    Bombardelli
    E,
    Curri
    SB,
    Della
    Loggia
    R,
    Del
    NP,
    Tubaro
    A,
    Gariboldi
    P.
    Complexes
    between
    phospholipids and vegetal derivatives of biological interest. Fitoterapia. 1989;60:1-9.
  9. 61.
    Semalty
    A,
    Semalty
    M,
    Rawat
    MSM,
    Franceschi
    F.
    Supramolecular
    phospholipids-polyphenolics
    interactions:
    the
    phytosome
    strategy
    to
    improve
    the
    bioavailability
    of
    phytochemicals.
    Fitoterapia.
    2010;81(5):306-314. doi:10.1016/j.fitote.2009.11.001.
  10. 62.
    Franceschi F, Giori A, Dall'Acqua S, et al. Phytosome: an unfamiliar approach for bioavailability and
    pharmacokinetic studies of silymarin. Fitoterapia. 2009;80(7):421-427.
  11. 63.
    Marena C, Lampertico M. Preliminary clinical development of silipide: a new complex of silybin in
    toxic liver disorders. Planta Med. 1991;57(2):A124-A125.
  12. 64.
    Bombardelli E, Spelta M. Phospholipid-polyphenol complexes: a new concept in skin care ingredients.
    Cosm Toil. 1991;106:69-76.
  13. 65.
    Singh RP, Gangadharappa HV, Mruthunjaya K. Phytosome complexation: a critical review. J Drug
    Deliv Sci Technol. 2016;35:201-210. doi:10.1016/j.jddst.2016.06.005.
  14. 66.
    Yanyu X, Yunmei S, Zhipeng C, Qineng P. The preparation of silybin-phospholipid complex and the
    study
    on
    its
    pharmacokinetics
    in
    rats.
    Int
    J
    Pharm.
    2006;307(1):77-82.
    doi:10.1016/j.ijpharm.2005.10.001.
  15. 67.
    Freag
    MS,
    Elnaggar
    YSR,
    Abdallah
    OY.
    Lyophilized
    phytosomal
    nanocarriers
    as
    platforms
    for
    enhanced diosmin delivery: optimization and ex vivo permeation. Int J Nanomedicine. 2013;8:2385-
    2397. doi:10.2147/IJN.S44851.
  16. 68.
    Manach
    C,
    Scalbert
    A,
    Morand
    C,
    Rémésy
    C,
    Jiménez
    L.
    Polyphenols:
    food
    sources
    and
    bioavailability. Am J Clin Nutr. 2004;79(5):727-747. doi:10.1093/ajcn/79.5.727.
  17. 69.
    Scalbert
    A,
    Williamson
    G.
    Dietary
    intake
    and
    bioavailability
    of
    polyphenols.
    J
    Nutr.
    2000;130(8S
    Suppl):2073S-2085S. doi:10.1093/jn/130.8.2073S.
  18. 70.
    Del
    Rio
    D,
    Rodriguez-Mateos
    A,
    Spencer
    JPE,
    Tognolini
    M,
    Borges
    G,
    Crozier
    A.
    Dietary
    (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against
    chronic diseases. Antioxid Redox Signal. 2013;18(14):1818-1892. doi:10.1089/ars.2012.4581.
  19. 71.
    Crozier
    A,
    Jaganath
    IB,
    Clifford
    MN.
    Dietary
    phenolics:
    chemistry,
    bioavailability,
    and
    effects
    on
    health. Nat Prod Rep. 2009;26(8):1001-1043. doi:10.1039/B802662A.
  20. 72.
    Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93
    intervention studies. Am J Clin Nutr. 2005;81(1 Suppl):243S-255S. doi:10.1093/ajcn/81.1.243S.
  21. 73.
    Holst
    B,
    Williamson
    G.
    Nutrients,
    and
    phytochemicals:
    from
    bioavailability
    to
    bioefficacy
    beyond
    antioxidants. Curr Opin Biotechnol. 2008;19(2):73-82. doi:10.1016/j.copbio.2008.03.003.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 40
  1. 74.
    Rein
    MJ,
    Renouf
    M,
    Cruz-Hernandez
    C,
    Actis-Goretta
    L,
    Thakkar
    SK,
    da
    Silva
    Pinto
    M.
    Bioavailability
    of
    bioactive
    food
    compounds:
    a
    challenging
    journey
    to
    bioefficacy.
    Br
    J
    Clin
    Pharmacol. 2013;75(3):588-602. doi:10.1111/j.1365-2125.2012.04425.x.
  2. 75.
    Parada J, Aguilera JM. Food microstructure affects the bioavailability of several nutrients. J Food Sci.
    2007;72(2):R21-R32. doi:10.1111/j.1750-3841.2007.00274.x.
  3. 76.
    McClements
    DJ.
    Enhancing
    the
    bioavailability
    of
    hydrophobic
    nutraceuticals:
    the
    role
    of
    food
    structure and colloidal delivery systems. Food Funct. 2010;1(1):32-47. doi:10.1039/C0FO0016B.
  4. 77.
    McClements
    DJ,
    Li
    F,
    Xiao
    H.
    The
    nutraceutical
    bioavailability
    classification
    scheme:
    classifying
    nutraceuticals
    according
    to
    factors
    limiting
    their
    oral
    bioavailability.
    Annu
    Rev
    Food
    Sci
    Technol.
    2015;6:299-327. doi:10.1146/annurev-food-032814-014043.
  5. 78.
    McClements
    DJ.
    Nanoemulsions
    versus
    microemulsions:
    terminology,
    differences,
    and
    similarities.
    Soft Matter. 2012;8:1719-1729. doi:10.1039/C2SM06903B.
  6. 79.
    McClements DJ, Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance,
    biological
    fate,
    and
    potential
    toxicity.
    Crit
    Rev
    Food
    Sci
    Nutr.
    2011;51(4):285-330.
    doi:10.1080/10408398.2011.559558.
  7. 80.
    Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties, and applications. Soft
    Matter. 2016;12:2826-2841. doi:10.1039/C5SM02958A.
  8. 81.
    Solans
    C,
    Izquierdo
    P,
    Nolla
    J,
    Azemar
    N,
    Garcia-Celma
    MJ.
    Nano-emulsions.
    Curr
    Opin
    Colloid
    Interface Sci. 2005;10(3-4):102-110. doi:10.1016/j.cocis.2005.06.004.
  9. 82.
    Tadros T, Izquierdo P, Esquena J, Solans C. Formation, and stability of nano-emulsions. Adv Colloid
    Interface Sci. 2004;108-109:303-318. doi:10.1016/j.cis.2003.10.023.
  10. 83.
    Jaiswal
    M,
    Dudhe
    R,
    Sharma
    PK.
    Nanoemulsion:
    an
    advanced
    mode
    of
    drug
    delivery
    system.
    3
    Biotech. 2015;5(2):123-127. doi:10.1007/s13205-014-0214-0.
  11. 84.
    Anton
    N,
    Benoit
    JP,
    Saulnier
    P.
    Design,
    and
    production
    of
    nanoparticles
    formulated
    from
    nano-
    emulsion
    templates—a
    review.
    J
    Control
    Release.
    2008;128(3):185-199.
    doi:10.1016/j.jconrel.2008.02.007.
  12. 85.
    Rao J, McClements DJ. Food-grade microemulsions and nanoemulsions: role of oil phase composition
    on
    formation
    and
    stability.
    Food
    Hydrocoll.
    2011;25(6):1413-1423.
    doi:10.1016/j.foodhyd.2011.02.014.
  13. 86.
    Date
    AA,
    Desai
    N,á
    Nagarsenker
    M.
    Parenteral
    microemulsions:
    an
    overview.
    Int
    J
    Pharm.
    2010;355(1-2):19-30.
  14. 87.
    Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization, and applications. Adv
    Drug Deliv Rev. 2001;47(2-3):165-196. doi:10.1016/S0169-409X(01)00105-3.
  15. 88.
    Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review
    of
    the
    state
    of
    the
    art.
    Eur
    J
    Pharm
    Biopharm.
    2000;50(1):161-177.
    doi:10.1016/S0939-
    6411(00)00087-4.
  16. 89.
    Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of
    drugs. Int J Pharm. 2002;242(1-2):121-128. doi:10.1016/S0378-5173(02)00180-1.
  17. 90.
    Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical
    dermal products. Int J Pharm. 2009;366(1-2):170-184. doi:10.1016/j.ijpharm.2008.10.003.
  18. 91.
    Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and
    future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
  19. 92.
    Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers:
    structure,
    preparation,
    and
    application.
    Adv
    Pharm
    Bull.
    2015;5(3):305-313.
    doi:10.15171/apb.2015.043.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 41
  1. 93.
    Severino
    P,
    Andreani
    T,
    Macedo
    AS,
    et
    al.
    Current
    state-of-art
    and
    current
    trends
    on
    lipid
    nanoparticles
    (SLN
    and
    NLC)
    for
    oral
    drug
    delivery.
    J
    Drug
    Deliv.
    2012;2012:750891.
    doi:10.1155/2012/750891.
  2. 94.
    Fangueiro JF, Silva AM, Garcia ML, Souto EB. Advanced formulations for topical delivery of anti-
    inflammatory drugs. Expert Opin Drug Deliv. 2014;11(10):1609-1622.
  3. 95.
    Schwarz C, Mehnert W, Lucks JS, Müller RH. Solid lipid nanoparticles (SLN) for controlled drug
    delivery:
    I.
    Production,
    characterization,
    and
    sterilization.
    J
    Control
    Release.
    1994;30(1):83-96.
    doi:10.1016/0168-3659(94)90047-7.
  4. 96.
    Radtke M, Müller RH. Nanostructured lipid drug carriers. New Drugs. 2001;2:48-52.
  5. 97.
    Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for
    topical use: drug release properties. J Control Release. 2000;66(2-3):115-126.
  6. 98.
    Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid
    lipid nanoparticle dispersions. Int J Pharm. 1998;168(2):221-229.
  7. 99.
    Fattal
    E,
    Barratt
    G.
    Nanotechnologies,
    and
    controlled
    release
    systems
    for
    the
    delivery
    of
    antisense
    oligonucleotides and siRNA. Adv Drug Deliv Rev. 2009;61(9):836-846.
  8. 100.
    Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers, and polymeric
    nanoparticles:
    mechanisms
    of
    controlling
    drug
    release.
    Chem
    Rev.
    2016;116(4):2602-2663.
    doi:10.1021/acs.chemrev.5b00346.
  9. 101.
    Makadia
    HK,
    Siegel
    SJ.
    Poly
    lactic-co-glycolic
    acid
    (PLGA)
    as
    biodegradable
    controlled
    drug
    delivery carrier. Polymers (Basel). 2011;3(3):1377-1397. doi:10.3390/polym3031377.
  10. 102.
    Danhier
    F,
    Ansorena
    E,
    Silva
    JM,
    Coco
    R,
    Le
    Breton
    A,
    Préat
    V.
    PLGA-based
    nanoparticles:
    an
    overview
    of
    biomedical
    applications.
    J
    Control
    Release.
    2012;161(2):505-522.
    doi:10.1016/j.jconrel.2012.01.043.
  11. 103.
    Jain
    RA.
    The
    manufacturing
    techniques
    of
    various
    drug
    loaded
    biodegradable
    poly(lactide-co-
    glycolide)
    (PLGA)
    devices.
    Biomaterials.
    2000;21(23):2475-2490.
    doi:10.1016/S0142-
    9612(00)00115-0.
  12. 104.
    Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-
    18. doi:10.1016/j.ijpharm.2004.04.013.
  13. 105.
    Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles.
    Pharm Res. 2009;26(5):1025-1058. doi:10.1007/s11095-008-9800-3.
  14. 106.
    Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-
    loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21. doi:10.1016/j.nano.2005.12.003.
  15. 107.
    Soppimath
    KS,
    Aminabhavi
    TM,
    Kulkarni
    AR,
    Rudzinski
    WE.
    Biodegradable
    polymeric
    nanoparticles
    as
    drug
    delivery
    devices.
    J
    Control
    Release.
    2001;70(1-2):1-20.
    doi:10.1016/S0168-
    3659(00)00339-4.
  16. 108.
    Li Y, MacDowell N, Langer R, et al. Polymer nanoparticles for drug delivery. Nat Rev Mater. 2021.
  17. 109.
    Kamaly
    N,
    Xiao
    Z,
    Valencia
    PM,
    Radovic-Moreno
    AF,
    Farokhzad
    OC.
    Targeted
    polymeric
    therapeutic
    nanoparticles:
    design,
    development,
    and
    clinical
    translation.
    Chem
    Soc
    Rev.
    2012;41(7):2971-3010. doi:10.1039/C2CS15344K.
  18. 110.
    Elsabahy
    M,
    Wooley
    KL.
    Design
    of
    polymeric
    nanoparticles
    for
    biomedical
    delivery
    applications.
    Chem Soc Rev. 2012;41(7):2545-2561. doi:10.1039/C1CS15219C.
  19. 111.
    Riley T, Govender T, Stolnik S, Xiong CD, Garnett MC, Illum L, Davis SS. Colloidal stability and
    drug incorporation aspects of micellar systems. Int J Pharm. 1999;191(2):147-156.
  20. 112.
    Jones MC, Leroux JC. Polymeric micelles—a new generation of colloidal drug carriers. Eur J Pharm
    Biopharm. 1999;48(2):101-111. doi:10.1016/S0939-6411(99)00039-9.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 42
  1. 113.
    Blanazs A, Armes SP, Ryan AJ. Self-assembled block copolymer aggregates: from micelles to vesicles
    and
    their
    biological
    applications.
    Macromol
    Rapid
    Commun.
    2009;30(4-5):267-277.
    doi:10.1002/marc.200800713.
  2. 114.
    Cabral
    H,
    Kataoka
    K.
    Progress
    of
    drug-loaded
    polymeric
    micelles
    into
    clinical
    studies.
    J
    Control
    Release. 2014;190:465-476. doi:10.1016/j.jconrel.2014.06.042.
  3. 115.
    Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug
    delivery platform. ACS Nano. 2008;2(8):1696-1702. doi:10.1021/nn800275r.
  4. 116.
    Hu
    CMJ,
    Zhang
    L.
    Nanoparticle-based
    combination
    therapy
    toward
    overcoming
    drug
    resistance
    in
    cancer. Biochem Pharmacol. 2012;83(8):1104-1111.
  5. 117.
    Peer
    D,
    Lieberman
    J.
    Special
    delivery:
    targeted
    therapy
    with
    small
    RNAs.
    Gene
    Ther.
    2011;18(12):1127-1133. doi:10.1038/gt.2011.56.
  6. 118.
    Yoo
    JW,
    Doshi
    N,
    Mitragotri
    S.
    Adaptive
    micro
    and
    nanoparticles:
    temporal
    control
    over
    carrier
    properties to facilitate drug delivery. Adv Drug Deliv Rev. 2011;63(14-15):1247-1256.
  7. 119.
    De
    Jong
    WH,
    Borm
    PJA.
    Drug
    delivery
    and
    nanoparticles:
    applications
    and
    hazards.
    Int
    J
    Nanomedicine. 2008;3(2):133-149.
  8. 120.
    Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio
    interface. Nat Mater. 2009;8(7):543-557. doi:10.1038/nmat2442.
  9. 121.
    Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity
    of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786. doi:10.1038/nnano.2012.207.
  10. 122.
    Tenzer
    S,
    Docter
    D,
    Kuharev
    J,
    et
    al.
    Rapid
    formation
    of
    plasma
    protein
    corona
    critically
    affects
    nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772-781. doi:10.1038/nnano.2013.181.
  11. 123.
    Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting
    capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137-143.
    doi:10.1038/nnano.2012.237.
  12. 124.
    Fadeel
    B,
    Garcia-Bennett
    AE.
    Better
    safe
    than
    sorry:
    understanding
    the
    toxicological
    properties
    of
    inorganic
    nanoparticles
    manufactured
    for
    biomedical
    applications.
    Adv
    Drug
    Deliv
    Rev.
    2010;62(3):362-374. doi:10.1016/j.addr.2009.11.008.
  13. 125.
    Nel
    A,
    Xia
    T,
    Mädler
    L,
    Li
    N.
    Toxic
    potential
    of
    materials
    at
    the
    nanolevel.
    Science.
    2006;311(5761):622-627. doi:10.1126/science.1114397.
  14. 126.
    Donaldson
    K,
    Stone
    V,
    Tran
    CL,
    Kreyling
    W,
    Borm
    PJA.
    Nanotoxicology.
    Occup
    Environ
    Med.
    2004;61(9):727-728. doi:10.1136/oem.2004.013243.
  15. 127.
    Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity
    of nanosized materials. Nat Nanotechnol. 2012;7(12):779-786. doi:10.1038/nnano.2012.207.
  16. 128.
    Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and
    in
    vitro
    toxicity
    of
    silver
    and
    gold
    particulates.
    Crit
    Rev
    Toxicol.
    2010;40(4):328-346.
    doi:10.3109/10408440903453074.
  17. 129.
    Khlebtsov N, Dykman L. Biodistribution, and toxicity of engineered gold nanoparticles: a review of in
    vitro and in vivo studies. Chem Soc Rev. 2011;40(3):1647-1671. doi:10.1039/C0CS00018C.
  18. 130.
    European
    Commission.
    Commission
    recommendation
    of
    10
    June
    2022
    on
    the
    definition
    of
    nanomaterial. Off J Eur Union. 2022;C229:1-5.
  19. 131.
    International
    Council
    for
    Harmonisation.
    ICH
    Q8(R2):
    Pharmaceutical
    development.
    Geneva:
    ICH;
    2009.
  20. 132.
    International Council for Harmonisation. ICH Q9(R1): Quality risk management. Geneva: ICH; 2023.
  21. 133.
    International
    Council
    for
    Harmonisation.
    ICH
    Q10:
    Pharmaceutical
    quality
    system.
    Geneva:
    ICH;
    2008.
  22. 134.
    International Council for Harmonisation. ICH Q1A(R2): Stability testing of new drug substances and
    products. Geneva: ICH; 2003.
Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 43
  1. 135.
    International Council for Harmonisation. ICH M3(R2): Nonclinical safety studies for the conduct of
    human clinical trials and marketing authorization for pharmaceuticals. Geneva: ICH; 2009.
  2. 136.
    International
    Council
    for
    Harmonisation.
    ICH
    S9:
    Nonclinical
    evaluation
    for
    anticancer
    pharmaceuticals. Geneva: ICH; 2009.
  3. 137.
    International Council for Harmonisation. ICH E6(R2): Good clinical practice. Geneva: ICH; 2016.
  4. 138.
    Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for
    reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
  5. 139.
    Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised
    trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.
  6. 140.
    Hooijmans
    CR,
    Rovers
    MM,
    de
    Vries
    RBM,
    Leenaars
    M,
    Ritskes-Hoitinga
    M,
    Langendam
    MW.
    SYRCLE's
    risk
    of
    bias
    tool
    for
    animal
    studies.
    BMC
    Med
    Res
    Methodol.
    2014;14:43.
    doi:10.1186/1471-2288-14-43.
  7. 141.
    Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that
    include
    randomised
    or
    non-randomised
    studies
    of
    healthcare
    interventions,
    or
    both.
    BMJ.
    2017;358:j4008. doi:10.1136/bmj.j4008.
  8. 142.
    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence
    and
    strength
    of
    recommendations.
    BMJ.
    2008;336(7650):924-926.
    doi:10.1136/bmj.39489.470347.AD.

How to cite this article:
Abhishek Tripathi, Harroshandeep Kaur Phull,Hepatotoxicity and Nephrotoxicity of Widely Used Medicinal
Herbs: A Critical Appraisal of Safety Evidence Against the Assumption That “Natural” Means Safe. (2026).
International Journal of
Pharmaceutical Research and Medicinal Plants
,
2
(5),27-44.
https://doi.org/10.61280/89qdmp44

Published by:

Informative Journals

Jadoun Science Publishing Group India

Abhishek Tripathi
/
International Journal of Pharmaceutical Research and Medicinal Plants
2026, Vol.02 (5), 27-44
https://informativejournals.com/journal/index.php/Journal_Medicinal_Plants
Page | 44